Lewter Lakeisha A, Fisher Janet L, Siemian Justin N, Methuku Kashi Reddy, Poe Michael M, Cook James M, Li Jun-Xu
Department of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo , Buffalo, New York 14214, United States.
Department of Pharmacology, Physiology & Neuroscience, School of Medicine, University of South Carolina , Columbia, South Carolina 29208, United States.
ACS Chem Neurosci. 2017 Jun 21;8(6):1305-1312. doi: 10.1021/acschemneuro.6b00447. Epub 2017 Feb 13.
Pain remains a challenging clinical condition and spinal GABA receptors are crucial modulators of pain processing. α2/α3-subtype GABA receptors mediate the analgesic actions of benzodiazepines. Positive allosteric modulators (PAMs) at α2/α3-subtype GABA receptors may have analgesic potential. Here we report a new selective α2/α3-subtype GABA receptor PAM in in vitro and in vivo pain assays. KRM-II-81 demonstrated similar efficacy at α1/α2/α3 GABA receptors and negligible efficacy at α4/α5/α6 GABA receptors, with α2 and α3-subtypes being 17- and 28-fold more potent than α1 subtypes in HEK-293T cells expressing GABA receptors with different α subunits. In contrast, KRM-II-18B showed significant efficacy at α1/α2/α3/ α5 subtypes, with similar potency at α1/α2/α3 subtypes. Both PAMs and morphine dose-dependently decreased 0.6% acetic acid- and 0.32% lactic acid-induced writhing. The effects of both PAMs were reversed by the benzodiazepine receptor antagonist flumazenil, confirming their action at the benzodiazepine binding site of GABA receptors. Both PAMS and morphine all dose-dependently reversed 0.32% lactic acid (but not 0.6% acetic acid) induced suppression of nesting behavior. Acetaminophen, but not the PAMs, reversed acid-depressed locomotor activity. Combined, these findings suggest that KRM-II-81 is a selective α2/α3 subtype GABA PAM with significant antinociceptive effects in chemical stimulation-induced pain in mice.
疼痛仍然是一种具有挑战性的临床病症,脊髓γ-氨基丁酸(GABA)受体是疼痛处理的关键调节因子。α2/α3亚型GABA受体介导苯二氮䓬类药物的镇痛作用。α2/α3亚型GABA受体的正变构调节剂(PAM)可能具有镇痛潜力。在此,我们在体外和体内疼痛试验中报告了一种新型选择性α2/α3亚型GABA受体PAM。KRM-II-81在α1/α2/α3 GABA受体上显示出相似的效力,而在α4/α5/α6 GABA受体上效力可忽略不计,在表达具有不同α亚基的GABA受体的人胚肾293T(HEK-293T)细胞中,α2和α3亚型的效力分别比α1亚型强17倍和28倍。相比之下,KRM-II-18B在α1/α2/α3/α5亚型上显示出显著效力,在α1/α2/α3亚型上具有相似的效力。两种PAM和吗啡均剂量依赖性地减少0.6%乙酸和0.32%乳酸诱导的扭体反应。苯二氮䓬类受体拮抗剂氟马西尼可逆转两种PAM的作用,证实它们在GABA受体的苯二氮䓬类结合位点起作用。两种PAM和吗啡均剂量依赖性地逆转0.32%乳酸(而非0.6%乙酸)诱导的筑巢行为抑制。对乙酰氨基酚可逆转酸抑制的运动活动,但PAM不能。综合来看,这些发现表明KRM-II-81是一种选择性α2/α3亚型GABA PAM,在小鼠化学刺激诱导的疼痛中具有显著的抗伤害感受作用。